Advisors Asset Management’s Regenxbio RGNX Stock Holding History

Advisors Asset Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,887	Closed	-$129K	–	1539
2022 Q1	$129K	Sell	3,887 -795	-17%	-$22.1K	﹤0.01%	1317
2021 Q4	$153K	Sell	4,682 -45	-1%	-$1.53K	﹤0.01%	1297
2021 Q3	$198K	Sell	4,727 -3	-0.1%	-$108	﹤0.01%	1212
2021 Q2	$184K	Sell	4,730 -18	-0.4%	-$644	﹤0.01%	1217
2021 Q1	$162K	Sell	4,748 -120	-2%	-$5.12K	﹤0.01%	1253
2020 Q4	$221K	Buy	4,868 +357	+8%	+$12.5K	﹤0.01%	1198
2020 Q3	$124K	Buy	4,511 +2,090	+86%	+$68.1K	﹤0.01%	1274
2020 Q2	$89.2K	Buy	+2,421	New	+$90.3K	﹤0.01%	1324

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Advisors Asset Management's RGNX Position: Q2 2022 in Review

Advisors Asset Management sold out of Regenxbio (RGNX) in Q2 2022, closing a stake of 3,887 shares — an estimated $129K sold.

Advisors Asset Management first reported a position in RGNX in Q2 2020 and held it in 8 quarters. The position peaked at $221K in Q4 2020. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2022.

Advisors Asset Management reported no remaining Regenxbio position as of Q2 2022 after selling out during the quarter.
Advisors Asset Management sold 3,887 Regenxbio shares in Q2 2022, an estimated $129K.
Advisors Asset Management first reported a position in Regenxbio in Q2 2020 and held it in 8 quarters.
Advisors Asset Management's Regenxbio position peaked at $221K in Q4 2020.
165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2022.

Based on Advisors Asset Management's 13F filing for Q2 2022, filed 8 Aug 2022.